Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients


LUND, Sweden, Feb. 26, 2022 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix® (imlifidase) has been granted early access post marketing authorization (Autorisation d’accès précoce) in France by French HAS (Haute Autorité de Santé) for use in the desensitization of highly sensitized adult patients prior to kidney transplant, in accordance with the patient population specified in the Marketing Authorization received from the European Medicines Agency (EMA)

Read More

Next Post

Global Conference On Pharmaceutical Sciences

On behalf of the Organizing Committee, we delighted to invite you to “Global Conference on Pharmaceutical sciences.” We organize conferences by offering a platform to all academicians, researchers and industry professionals. Aver Pharmaceutical Sciences will be scheduled on wide range of topics and it will be helpful for scientific fraternity […]